Korro Bio (NASDAQ:KRRO) Major Shareholder Paul Edward Walker Buys 207,100 Shares

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Paul Edward Walker purchased 207,100 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was bought at an average cost of $11.11 per share, with a total value of $2,300,881.00. Following the purchase, the insider owned 1,297,893 shares of the company’s stock, valued at $14,419,591.23. This represents a 18.99% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Korro Bio Trading Up 12.6%

Korro Bio stock traded up $1.45 during trading hours on Friday, reaching $12.95. 552,892 shares of the stock were exchanged, compared to its average volume of 237,193. Korro Bio, Inc. has a twelve month low of $5.20 and a twelve month high of $55.89. The company has a market cap of $121.97 million, a P/E ratio of -1.38 and a beta of 2.98. The stock has a 50 day moving average of $10.90 and a two-hundred day moving average of $20.23.

Korro Bio (NASDAQ:KRRO) last issued its earnings results on Tuesday, March 17th. The company reported ($5.32) EPS for the quarter, missing the consensus estimate of ($1.93) by ($3.39). The firm had revenue of $1.29 million during the quarter, compared to analyst estimates of $0.43 million. Korro Bio had a negative net margin of 1,199.53% and a negative return on equity of 68.87%. On average, analysts expect that Korro Bio, Inc. will post -9.52 earnings per share for the current fiscal year.

Analyst Ratings Changes

KRRO has been the topic of a number of research analyst reports. Piper Sandler downgraded Korro Bio from an “overweight” rating to a “neutral” rating and set a $11.00 target price on the stock. in a report on Thursday, November 13th. Wall Street Zen downgraded Korro Bio from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. HC Wainwright reaffirmed a “neutral” rating on shares of Korro Bio in a research note on Thursday, November 13th. Royal Bank Of Canada downgraded Korro Bio from an “outperform” rating to a “sector perform” rating in a research note on Thursday, November 13th. Finally, Raymond James Financial upgraded shares of Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 price target on the stock in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $44.50.

Trending Headlines about Korro Bio

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target (~74% upside vs. the recent share level), which can attract momentum buyers and institutional interest. Raymond James Upgrade
• Positive Sentiment: Multiple large shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed purchases of ~207,100 shares each at about $11.11 (~$2.3M per filing), increasing their stakes — a strong insider/major‑holder vote of confidence that can support the stock. Insider / Major Holder Buys
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for potential treatment of hyperammonemia, is advancing a GalNAc candidate for alpha‑1 antitrypsin deficiency (on track for a development candidate nomination in Q2 2026), and completed an oversubscribed $85M private placement — management says cash runway now extends into H2 2028, reducing near‑term financing risk. Corporate Update & Cash Raise
• Neutral Sentiment: Revenue modestly beat expectations ($1.29M vs. ~$0.42M est.), showing some commercial or other revenue pickup, but the dollar amounts are small relative to R&D burn — limited immediate impact on profitability. Earnings Press Release
• Negative Sentiment: Large quarterly loss: KRRO reported a Q4 EPS loss of ($5.32) vs. consensus (~($1.93)), driving very negative margins and return‑on‑equity metrics — a reminder of high execution risk and binary clinical development outcomes that can trigger volatility. Q4 Results & EPS Miss

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd boosted its position in Korro Bio by 31.1% during the 4th quarter. XTX Topco Ltd now owns 57,067 shares of the company’s stock worth $457,000 after buying an additional 13,529 shares during the period. Quadrature Capital Ltd acquired a new position in Korro Bio in the 4th quarter valued at approximately $217,000. Engineers Gate Manager LP bought a new position in shares of Korro Bio during the fourth quarter valued at $215,000. Guggenheim Capital LLC bought a new position in shares of Korro Bio during the fourth quarter valued at $84,000. Finally, Jain Global LLC acquired a new position in shares of Korro Bio during the fourth quarter worth $85,000. Institutional investors own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.